DCTH (Delcath Systems) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Delcath Systems Debt-to-Asset?

Delcath Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.11 Mil. Delcath Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.93 Mil. Delcath Systems's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $76.59 Mil. Delcath Systems's debt to asset for the quarter that ended in Dec. 2024 was 0.01.

Delcath Systems Debt-to-Asset Historical Data

The historical data trend for Delcath Systems's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Debt-to-Asset Chart

Delcath Systems Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.09

0.48

0.89

0.26

0.01

Delcath Systems Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.26	0.24	0.17	0.10	0.01

Competitive Comparison of Delcath Systems's Debt-to-Asset

For the Medical Devices subindustry, Delcath Systems's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Delcath Systems's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Debt-to-Asset falls into.

Delcath Systems Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Delcath Systems's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.105	+	0.933)	/	76.589
	=	0.01

Delcath Systems's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.105	+	0.933)	/	76.589
	=	0.01

Delcath Systems (NAS:DCTH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Delcath Systems Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Delcath Systems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (NAS:DCTH) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DV3R:Germany DV3R:Germany

Address

566 Queensbury Avenue, Queensbury, NY, USA, 12804

Website

https://www.delcath.com

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Executives

Gil Aharon	director	15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Salamon Steven A J	director	25 ADMIRAL ROAD, TORONTO A6 M5R 2L4
Vojo Vukovic	officer: See Remarks	C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Gerard J Michel	director, officer: Chief Executive Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Sandra Pennell	officer: See Remarks	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
David L. Hoffman	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
John Purpura	officer: EVP, Regulatory Affairs	600 FIFTH AVENUE, 23RD FLOOR, NEW YORK NY 10020
John Richard Sylvester	director	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Rosalind Advisors, Inc.	director, other: See Remarks	15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Kevin Muir	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Anthony Dias	officer: Vice President of Finance	C/O SEACHANGE INTERNATIONAL, 50 NAGOG PARK, ACTON MA 01720
Johnny John	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Elizabeth Czerepak	director	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Christine Padula	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Simon Pedder	director	1001 MAIN STREET, SUITE 600, BUFFALO NY 14203